Table 1 Baseline characteristics of patients with diabetes and their matched general population comparison cohort

From: Ten-year cardiovascular risk in diabetes patients without obstructive coronary artery disease: a retrospective Western Denmark cohort study

  Diabetes patients (n = 5734) General population (n = 28,670)
N % N %
Male sex 2997 52.3 14,985 52.3
Median age (IQR) 62 years (53-70) 62 years (53-70)
Family history of ischemic heart diseasea
 Yes 2058 35.9
 Missing 670 11.7
Smokinga
 Active 1070 18.7
 Former 2024 35.3
 Never 2008 35.0
 Missing 632 11.0
CAG procedural indicationa     
 STEMI 112 2.0
 NSTEMI 259 4.5
 Unstable AP 190 3.3
 Stable AP 2666 46.5
 Arrhythmia 228 4.0
 Valvular disease 665 11.6
 Cardiomyopathy 613 10.7
 Other 899 15.7
 Missing 102 1.8
Comorbidity
 Diabetes 5734 100.0 2041 7.1
 Chronic pulmonary disease 626 10.9 1123 3.9
 Hypertension 3362 58.6 3110 10.8
 Peripheral artery disease 214 3.7 456 1.6
 Heart failure 991 17.3 262 0.9
 Atrial fibrillation 1070 18.7 979 3.4
 Ischemic stroke 201 3.5 285 1.0
 Hemorrhagic stroke 12 0.2 69 0.2
 MI < 30 days after inclusion 2 0.0 6 0.0
Comedication
 Aspirin 3535 61.6 3455 12.1
 ADP-inhibitors 261 4.6 286 1.0
 Vitamin K-antagonists 909 15.9 830 2.9
 DOAC 182 3.2 148 0.5
 Statin 4140 72.2 5423 18.9
 Beta-blocker 3118 54.4 3227 11.3
 ACE-inhibitor 2659 46.4 3832 13.4
 ARB 1698 29.6 2870 10.0
 Thiazide 1209 21.1 2879 10.0
 Calcium-blocker 2050 35.8 3669 12.8
 Insulin 1631 28.4 568 2.0
  Non-insulin anti-diabetes agents 3658 63.8 1484 5.2
  1. ACE angiotensin converting enzyme, ADP adenosine diphosphate, AP angina pectoris, ARB angiotensin-II receptor blocker, CAG coronary angiography, DOAC direct oral anti-coagulant, MI myocardial infarction, NSTEMI non ST-elevation myocardial infarction, SD standard deviation, STEMI ST-elevation myocardial infarction
  2. aData provide by the Western Denmark Heart Registry. Unavailable for the general population